本季度信息
华润医药于2026年10月23日发布的公告显示，其附属公司昆药集团截至2026年9月30日止九个月的营业总收入约为27.22亿元（人民币，下同），与2025年同期的47.51亿元相比，同比下降约42.7%。期内净利润由上年同期3.23亿元转为亏损3.63亿元，降幅约为212%。
公告同时显示，截至报告期末，昆药集团总资产约为105.24亿元，总负债约为40.80亿元，所有者权益约为64.44亿元。与此同时，期末现金及现金等价物余额约为3.69亿元。
业务分项
（公告未披露具体业务板块营收与增幅情况，故此处暂不列示。）
高管解读
（公告未公开高管相关表述，故此处暂不列示。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.